Finance

Lists
OBIO:NASDAQ
Orchestra Biomed Holdings Inc
5,71 USD
+1,24%
(+0,070) 1D
15-окт., 12:35:56 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OBIO...
Open
5,68 USD
High
5,85 USD
Low
5,66 USD
Mkt. cap
343,20 млн
Avg. vol.
339,90 миң
Volume
82,62 миң
52-wk high
6,50 USD
52-wk low
3,26 USD
EPS
-1,01 USD
Beta
0,52
Shares outstanding
60,10 млн
No. of employees
86
Open
5,68 USD
High
5,85 USD
Low
5,66 USD
Mkt. cap
343,20 млн
Avg. vol.
339,90 миң
Volume
82,62 миң
52-wk high
6,50 USD
52-wk low
3,26 USD
EPS
-1,01 USD
Beta
0,52
Shares outstanding
60,10 млн
No. of employees
86
News stories
From web sources and news partners
About Orchestra Biomed Holdings Inc
CEO-
Employees86
Founded2018
Headquarters-
SectorMedical device
Websiteorchestrabiomed.com
Analyst ratings
Based on 5 analysts giving stock ratings to OBIO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OBIO in the last 3 months.
Highest
Current 5,71 USD
15,00 USD (+162,70%)
Average
11,60 USD (+103,15%)
Lowest
10,00 USD (+75,13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew O'Brien
Piper Sandler
Buy
Maintained
12,00 USD
+110,2%
10/15/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
10,00 USD
+75,1%
10/05/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
11,00 USD
+92,6%
10/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
15,00 USD
+162,7%
09/25/2026
Marie Thibault
BTIG
Buy
Upgraded
10,00 USD
+75,1%
09/10/2026
Unknown Analyst
BTIG
Hold
Maintained
-
-
07/09/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
10,00 USD
+75,1%
05/18/2026
Matt Miksic
Barclays
Buy
Reiterated
13,00 USD
+127,7%
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
20,00 USD
+250,3%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
861,00 миң
30,92 млн
110,00 миң
88,00 миң
Cost of goods sold
49,00 миң
51,00 миң
32,00 миң
25,00 миң
Cost of revenue
49,00 миң
51,00 миң
32,00 миң
25,00 миң
Research and development expenses
14,03 млн
16,82 млн
15,78 млн
16,59 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,10 млн
7,29 млн
6,37 млн
5,83 млн
Operating expense
21,12 млн
24,11 млн
22,15 млн
22,42 млн
Total operating expenses
21,17 млн
24,16 млн
22,19 млн
22,44 млн
Operating income
-20,31 млн
6,75 млн
-22,08 млн
-22,36 млн
Other non operating income
-
254,00 миң
-376,00 миң
-517,00 миң
EBT including unusual items
-20,83 млн
6,24 млн
-20,69 млн
-23,76 млн
EBT excluding unusual items
-20,83 млн
6,24 млн
-22,93 млн
-23,80 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,83 млн
6,24 млн
-20,69 млн
-23,76 млн
Net profit margin
-2 419,05%
20,20%
-18 810,00%
-26 994,32%
Earnings per share
-0,40
0,26
-0,33
-0,37
Interest and investment income
-
752,00 миң
-
-
Interest expense
-515,00 миң
-1,52 млн
-480,00 миң
-927,00 миң
Net interest expenses
-515,00 миң
-763,00 миң
-480,00 миң
-927,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,23 млн
6,84 млн
-21,99 млн
-22,26 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору